|3.||Wounds and Injuries (Trauma)
|1.||Gan, Bing Siang: 13 articles (01/2014 - 06/2003)|
|2.||Hentz, Vincent R: 9 articles (06/2014 - 09/2002)|
|3.||Bayat, Ardeshir: 9 articles (01/2014 - 06/2003)|
|4.||O'Gorman, David B: 8 articles (01/2014 - 01/2006)|
|5.||De Smet, Luc: 6 articles (04/2014 - 08/2008)|
|6.||Degreef, Ilse: 6 articles (04/2014 - 08/2008)|
|7.||Badalamente, Marie A: 5 articles (09/2015 - 09/2002)|
|8.||Hurst, Lawrence C: 5 articles (09/2015 - 09/2002)|
|9.||Satish, Latha: 5 articles (01/2015 - 01/2008)|
|10.||Gerber, Robert A: 5 articles (04/2014 - 01/2011)|
|1.||Collagenases (Collagenase)FDA Link
09/01/2013 - "The use of collagenase injection in the treatment of palmar form of Dupuytren's disease gives good results in the short and medium terms. "
12/01/2014 - "The use of collagenase appears to be an effective and safe method for the treatment of Dupuytren's contracture. "
05/01/1996 - "These results indicate that collagenase may be effective in enzymatic fasciotomy of residual-stage Dupuytren's disease."
09/01/2002 - "The results of these studies indicate that nonoperative collagenase injection therapy for Dupuytren's disease is both a safe and effective method of treating this disorder in the majority of patients as an alternative to surgical fasciectomy. "
06/01/2015 - "Collagenase is a safe and effective outpatient-based treatment for Dupuytren's contracture, which may be useful in controlling surgical waiting lists. "
|2.||Microbial Collagenase (Clostridiopeptidase A)IBA
12/01/2010 - "Collagenase clostridium histolyticum is the first Food and Drug Administration-approved, nonsurgical treatment option for adult Dupuytren's contracture patients with a palpable cord that is highly effective and well tolerated. "
08/01/2015 - "Collagenase clostridium histolyticum injection proved to be an effective and safe treatment for Dupuytren contracture. "
09/01/2011 - "Collagenase clostridium histolyticum is a novel treatment for Dupuytren's contracture, approved by the U.S. "
12/01/2013 - "This study was designed to provide comparative information on the safety and efficacy of injection with collagenase clostridium histolyticum (CCH) and fasciectomy for patients with Dupuytren's contracture (DC). "
07/01/2015 - "Collagenase Clostridium Histolyticum versus Limited Fasciectomy for Dupuytren's Contracture: Outcomes from a Multicenter Propensity Score Matched Study."
11/01/2009 - "Several studies indicate that MMPs and TIMPs may play a key role in the onset or progression of Dupuytren's disease and related disorders. "
02/01/2013 - "Matrix metalloproteinases (MMPs) are expressed in Dupuytren's contracture and play a role in matrix remodeling. "
11/01/2009 - "In the future, a treatment that downregulates TIMPs but increases the activity of MMPs may be an appropriate therapy for Dupuytren's disease."
11/01/2009 - "The balance between MMPs and their natural inhibitors is disturbed in patients with Dupuytren's disease. "
11/01/2009 - "Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease."
06/01/2012 - "MMP-14 and MMP-2 are key metalloproteases in Dupuytren's disease fibroblast-mediated contraction."
03/01/2007 - "A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease."
09/01/2008 - "We have previously demonstrated that gene expression levels of matrix metalloproteinases (MMPs), related metalloproteinases "a disintegrin and metalloproteinase with thrombospontin motifs" (ADAMTSs), and tissue inhibitors of metalloproteinases (TIMPs) differed when comparing palmar fascia from 19 patients with Dupuytren's disease (DD) with 19 disease-free controls. "
10/01/2003 - "Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease."
11/01/1992 - "The raised levels of serum lipids appeared to be associated with the pathogenesis of Dupuytren's disease, and this may help to explain the high incidence of Dupuytren's disease in alcoholic, diabetic and epileptic patients, since these conditions are also associated with raised serum lipid levels."
11/01/1992 - "We studied prospectively the relationship between serum lipids and Dupuytren's disease of the hand in 85 patients, 65 men and 20 women. "
11/01/1992 - "Lipids and Dupuytren's disease."
06/01/2011 - "Improved postoperative outcome of segmental fasciectomy in Dupuytren disease by insertion of an absorbable cellulose implant."
06/01/2011 - "In this case-control prospective study, we investigated if we could improve the surgical outcome of interrupting strands in Dupuytren disease by creating a blocking effect with an absorbable cellulose implant, a known absorbable adhesion barrier. "
08/01/1991 - "The objective of this study was to determine if fibroblasts from patients with Dupuytren's contracture have an intrinsic aberration in collagen production or whether local factors govern the collagen changes in Dupuytren's contracture. "
01/01/1990 - "The search for the causative factors in Dupuytren's disease has historically progressed form gross anatomical dissection, through microscopical tissue studies, to the biochemistry of the collagen produced. "
04/01/1984 - "Biochemical studies on the collagen of the palmar aponeurosis affected with Dupuytren's disease."
06/01/1981 - "No alterations of the molecular structure or the state of macromolecular aggregation of the collagen in Dupuytren's disease were detected by wide or low-angle x-ray diffraction studies or by transmission electron microscopy. "
12/01/2014 - "Dupuytren's disease (DD) is a fibroproliferative pathology that affects the palmar aponeurosis causing the development of nodules and collagen cords and the progressive flexion of the fingers. "
|8.||Transforming Growth Factor beta (TGF-beta)IBA
02/01/2002 - "In this study, we tested for an association between Dupuytren's disease (DD) and a novel insertion polymorphism within the 5'-untranslated region (5'-UTR), of the TGFbeta(2) gene. "
06/01/2003 - "Transforming growth factor beta 1 (TGF-beta 1) is a key fibrogenic cytokine that has been shown to stimulate fibroblast proliferation and extracellular matrix deposition and has been implicated in the pathogenesis of Dupuytren disease. "
04/01/2002 - "TGF(beta) appears to be the key cytokine in the fibrogenic nature of Dupuytren's disease. "
03/01/1996 - "The role of transforming growth factor beta in Dupuytren's disease."
01/01/1995 - "Because both these features characterize Dupuytren's contracture, we investigated a possible role for TGF-beta in the etiology of this disorder. "
01/01/2005 - "Oxidative stress and production of free radicals may be important factors in the pathogenesis of Dupuytren's disease. "
11/01/1988 - "Free radicals and Dupuytren's contracture."
01/23/1988 - "Free radicals and Dupuytren's contracture."
11/28/1987 - "Production of free radicals may be an important factor in the pathogenesis of Dupuytren's contracture. "
11/28/1987 - "Free radicals and Dupuytren's contracture."
|10.||Transforming Growth Factor beta1 (TGF beta 1)IBA
03/01/2002 - "To our knowledge, this is the first report of a case-control association study in Dupuytren's disease using single nucleotide polymorphisms in TGF-beta1."
03/01/2002 - "Previous studies have implicated TGF-beta1 in Dupuytren's disease, suggesting that it may represent a candidate susceptibility gene for this condition. "
10/01/2006 - "Myofibroblasts and TGF-beta1 are implicated in Dupuytren's contracture. "
08/01/2003 - "The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1."
03/01/2002 - "Our observations suggest that common TGF-beta1 polymorphisms are not associated with a risk of developing Dupuytren's disease. "
11/01/2012 - "Steroid injections in combination with needle aponeurotomy as a treatment method for Dupuytren disease: suggestions for increasing the research evidence."
07/01/1999 - "We studied tissue from 20 patients with Dupuytren's disease, four samples of normal palmar fascia from patients undergoing carpal tunnel decompression and tissue from ten patients who had received perinodular injections of depomedrone into the palm five days before operation. "
06/01/2011 - "Injections into the palmar hand for trigger finger, palmar flexor tenosynovitis, and Dupuytren contracture can be very painful. "
01/01/2014 - "Although the mainstay of treatment accepted by most is surgical, use of collagenase injections aimed at chemically disintegrating pathologic cords may emerge as an important addition to the armamentarium of treatments for Dupuytren's disease."
06/01/2015 - "The aim of this study is to compare the efficacy of collagenase injections with that of fasciectomy in the treatment of Dupuytren's contracture. "
01/01/1991 - "TEC used for 2 weeks preoperatively has eliminated finger amputation in severe cases of Dupuytren's disease. "
11/01/2013 - "This was performed for a 59-year-old man who developed the condition in his ring finger, following Vth ray amputation for severe Dupuytren's disease. "
07/01/2009 - "Dupuytren's disease: a predominant reason for elective finger amputation in adults."
12/01/1993 - "Alternatives to finger amputation should be sought in difficult cases of Dupuytren's disease."
12/01/1993 - "23 finger amputations in 19 patients operated on for Dupuytren's disease were reviewed 6 months to 8.5 years after operation (mean 4 years). "
03/01/2001 - "Radiotherapy optimization in early-stage Dupuytren's contracture: first results of a randomized clinical study."
05/01/2015 - "Radiotherapy with soft X-rays in Dupuytren's disease - successful, well-tolerated and satisfying."
02/01/2010 - "Radiotherapy in early-stage Dupuytren's contracture. "
11/01/2001 - "[Radiotherapy of early stage Dupuytren disease. "
03/01/2001 - "Radiotherapy (RT) can prevent progression of Dupuytren's contracture (DC). "
01/01/2000 - "The purpose of this study was the development of a non-invasive preoperative soft-tissue extension device for the treatment of patients with Dupuytren's contracture grade III and IV according to the classification of Tubiana, based on the experience of continuous extension treatment using the external fixator of Messina. "
03/01/2002 - "We describe a technique of continuous preoperative soft-tissue distraction in Dupuytren's contracture grade IV using an unilateral external fixator which is simple to apply. "
12/01/1996 - "Postoperative traction, using the "S" Quattro external fixation device, improved the initial correction in 17 of 18 fingers treated by limited fasciectomy for severe proximal interphalangeal joint contracture in Dupuytren's disease. "
01/01/1998 - "In 13 patients (18 fingers) we used two types of external fixator as progressive static splints for the preoperative correction of the deformities of severe Dupuytren's disease before conventional fasciectomy. "